Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Courtney D. DiNardo et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S. Topp, Hagop M. Kantarjian, Gary J. Schiller et al.|The Lancet Oncology|2014Cited by 1.3k
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor StudyRavi Bhatia, Daniel J. Weisdorf, Liton Francisco et al.|Blood|2007Cited by 536
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agentsIbrahim Aldoss, Vinod Pullarkat, Sanjeet Dadwal et al.|Blood Advances|2019Cited by 84